Sandoz Will Launch Biosimilar Epoetin Alfa In Europe At Up To 30 Percent Discount To Branded Products
This article was originally published in The Pink Sheet Daily
Executive Summary
EU approval further demonstrates need for U.S. follow-on pathway, Sandoz VP-Global Head of Biopharma Development Ajaz Hussain tells “The Pink Sheet” DAILY.